Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety.
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted in parallel to the circulation after a meal. Intravenous (IV) GLP-1 has an inhibitory effect on gastric emptying, hunger and food intake in man. In rodents, central administration of GLP-2 increases satiety similar to GLP-1. The aim of the present study was to assess the effect of IV administered GLP-2 on gastric emptying and feelings of hunger in human volunteers. In eight (five men) healthy subjects (age 31.1+/-2.9 years and BMI 24.1+/-1.0 kg m(-2)), scintigraphic solid gastric emptying, hunger ratings (VAS) and plasma concentrations of GLP-2 were studied during infusion of saline or GLP-2 (0.75 and 2.25 pmol kg(-1) min(-1)) for a total of 180 min. Concentrations of GLP-2 were elevated to a maximum of 50 and 110 pmol l(-1) for 0.75 and 2.25 pmol kg(-1) min(-1) infusion of GLP-2, respectively. There was no effect of GLP-2 on either the lag phase (29.5+/-4.4, 26.0+/-5.2 and 21.2+/-3.6 min for saline, GLP-2 0.75 or 2.25 pmol kg(-1) min(-1), respectively) or the half emptying time (84.5+/-6.1, 89.5+/-17.8 and 85.0+/-7.0 min for saline, GLP-2 0.75 or 2.25 pmol kg(-1) min(-1), respectively). The change in hunger rating after the meal to 180 min was also unaffected by infusion of GLP-2. GLP-2 does not seem to mediate the ileal brake mechanism.
Department of Gastroenterology and Hepatology, Karolinska Hospital, Karolinska Institutet, SE-171 76, Stockholm, Sweden. Peter.Thelin.Schmidt@medks.ki.se
P T
PT
Schmidt
E
E
Näslund
P
P
Grybäck
H
H
Jacobsson
B
B
Hartmann
J J
JJ
Holst
P M
PM
Hellström
D000328:Adult; D001069:Appetite Regulation / Q000187:drug effects; D018592:Cross-Over Studies; D005746:Gastric Emptying / Q000187:drug effects*; D052216:Glucagon-Like Peptide 1; D053767:Glucagon-Like Peptide 2; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010455:Peptides / Q000008:administration & dosage* / Q000494:pharmacology*; D012527:Satiation / Q000187:drug effects*
D053767:Glucagon-Like Peptide 2; D010455:Peptides; D052216:Glucagon-Like Peptide 1